Prostate Cancer Screening With Abbreviated MRI Protocol
Key facts
- Who runs it
- Masaryk Memorial Cancer Institute
- Where
- Czechia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 300 people, planned
- Started
- 1 May 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- magnetic resonance
- serum PSA examination
- Biopsy
- Record updated
- 10 November 2026
Who can take part
- Age
- 50 years to 69 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 50-69 years
- Life expectancy over 10 years
- Ability to undergo all planned procedures (without contraindications to MRI or biopsy)
- No known prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)
- No PSA test or prostate MRI in the past 2 years
- No signs of prostatitis or urinary tract infection in the past 6 months
- Signed informed consent
Who cannot take part
- Contraindications to MRI
- Hip replacement
- Known BRCA1/BRCA2 mutation
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is not yet available. According to international recommendations, the preventive PSA sampling used in clinical practice is not suitable because of the concurrent detection of clinically insignificant carcinomas in a major proportion of tests. These clinically non-significant cancers make up a significant and increasing proportion with age. Detection of non-significant cancers burdens the health care system and patients with the care that has no positive impact on their health. Current preventive serum prostate-specific antigen (PSA) testing does not distinguish benign hyperplasia and nonsignificant carcinoma from clinically significant cancer. It is therefore not suitable for full-scale screening.
Read full original descriptionShow less
According to current guidelines, magnetic resonance imaging (MRI) is indicated only in patients with an increased risk of cancer for detection or staging after biopsy and is not used for screening. According to recent studies, MRI has detected an increased proportion of significant cancers in the general population compared to screening based on PSA, while fewer clinically insignificant cancers have been detected. In screening, a shorter examination protocol without contrast medium (biparametric MRI) is used with a lower cost per examination, allowing to increase both the number of patients examined and patient comfort.
The main objective of the project is to assess the contribution of imaging in the screening of clinically significant prostate cancer and to validate the published results in the Czech population, and extend the screening model by the second round of examinations and additional laboratory markers. The secondary aim is to design a subsequent study with a larger number of participants allowing statistical evaluation, similar to the successful breast cancer screening.
The group in the trial
- Preventive prostate examination by bpMRITreatment being tested
The cohort consists of patients: * with age 50-69 years * without any contraindications to MRI or biopsy * without known status of prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction) * without known BRCA mutation * without PSA test or prostate MRI in the past 2 years * without any signs of prostatitis or urinary tract infection in the past 6 months.
Treatment: magnetic resonance, serum PSA examination, and Biopsy
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ProstaPilot: Prostate Cancer Screening Using MRI With an Abbreviated Protocol
- Publications
- Exploring motivations and barriers in prostate cancer screening: lessons from a volunteer-based MRI screening study.Frontiers in public health, 2025
- Record updated
- 10 November 2026